From: Gender-specific relationship between thigh muscle and fat mass and brain amyloid-β positivity
Variables | Males | Females | ||||
---|---|---|---|---|---|---|
Total (n = 134) | Aβ (−) (n = 90) | Aβ (+) (n = 44) | Total (n= 106) | Aβ (−) (n = 65) | Aβ (+) (n = 41) | |
Cognitive stage | ||||||
NC | 62 (46.3%) | 49 (54.4%)∗ | 13 (29.5%)∗ | 61 (57.5%) | 43 (66.2%)∗ | 18 (43.9%)∗ |
MCI | 72 (53.7%) | 41 (45.6%)∗ | 31 (70.5%)∗ | 45 (42.5%) | 22 (33.8%)∗ | 23 (56.1%)∗ |
Demographics | ||||||
Age, years | 71.3±6.7 | 70.5±7.2∗ | 72.8±5.3∗ | 69.9±8.1 | 68.9±8.3 | 71.5±7.5 |
Education, years | 13.7±4.0 | 14.2±3.5 | 12.8±4.6 | 12.0±4.8 | 12.4±4.7 | 11.2±4.9 |
APOE, e4 carrier | 47 (35.1%) | 19 (21.1%)∗ | 28 (63.6%)∗ | 33 (31.1%) | 10 (15.4%)∗ | 23 (56.1%)∗ |
Hypertension | 64 (47.8%) | 46 (51.1%) | 18 (40.9%) | 49 (46.2%) | 29 (44.6%) | 20 (48.8%) |
Diabetes | 32 (23.9%) | 23 (25.6%) | 9 (20.5%) | 17 (16.0%) | 11 (16.9%) | 6 (14.6%) |
Body composition | ||||||
BMI, kg/m2 | 24.0±2.6 | 24.56±2.57∗ | 22.85±2.41∗ | 23.5±2.9 | 24.01±2.91∗ | 22.69±2.84∗ |
LASMI, kg/m2 | 5.57±0.47 | 5.62±0.50 | 5.48±0.39 | 4.64±0.44 | 4.72±0.42∗ | 4.50±0.44∗ |
GFFP, % | 18.72±4.05 | 19.48±4.02∗ | 17.15±3.66∗ | 25.19±4.54 | 25.28±4.08 | 25.05±5.24 |
Aβ deposition | ||||||
Centiloid | 27.0±42.1 | 1.3±6.7∗ | 79.6±34.2∗ | 27.1±37.1 | 2.2±6.3∗ | 66.4±30.9∗ |
Cognitive tests | ||||||
SVLT recall | 4.4±2.9 | 5.2±2.9∗ | 2.9±2.3∗ | 5.2±3.4 | 6.1±3.1∗ | 3.5±3.2∗ |
RCFT recall | 13.2±6.9 | 15.0±7.0∗ | 9.7±5.1∗ | 11.0±6.9 | 13.0±6.7∗ | 7.8±6.1∗ |
K-BNT | 46.7±7.8 | 47.7±7.3∗ | 44.7±8.5∗ | 43.3±9.7 | 45.1±8.6∗ | 40.3±10.8∗ |
RCFT copying | 32.2±4.5 | 32.9±3.1∗ | 30.7±6.2∗ | 30.4±7.2 | 31.7±5.7∗ | 28.3±8.8∗ |
DSB | 3.9±1.0 | 3.9±1.0 | 3.9±1.0 | 3.9±1.4 | 4.1±1.5 | 3.7±1.3 |
Stroop CR | 73.0±24.9 | 76.1±23.0∗ | 66.8±27.6∗ | 80.5±28.5 | 88.0±25.7∗ | 68.0±28.7∗ |